Address
5980 Horton Street
EmeryVille, CA 94608
United States of America (the)
Phone
510 250 7800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
114
First IPO Date
September 30, 2021
| Name | Title | Pay | Year Born |
| Matthew W. Foehr | President, Chief Executive Officer & Director | 1.07M | 1973 |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer | 730,741 | 1968 |
| Charles S. Berkman | Chief Legal Officer & Secretary | 742,065 | 1969 |
| Bill Harriman | Senior Vice President of Antibody Discovery | 0 | N/A |
| Christel Iffland | Senior Vice President of Antibody Technologies | 0 | N/A |
| Todd Pettingill | Vice President of Business Development & Strategy | 0 | N/A |
| Cia McCaffrey | Senior Vice President of People & Talent | 0 | N/A |
| Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research | 0 | N/A |
| Bob Chen | Senior Vice President of Discovery Systems | 0 | N/A |
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.